Breast Cancer
Conditions
Brief summary
18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET). In this prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease and their potential sensitivity to endocrine therapy in ER-positive breast cancer.
Interventions
DIAGNOSTIC_TEST18F-FES PET/CT scan
Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* suspected or confirmed metastatic ER-positive breast cancer; * 18F-FDG PET/CT within two weeks; * signed written consent.
Exclusion criteria
* pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Standardized uptake value of 18F-FES in BC | through study completion, an average of 1 year | The max standard uptake value (SUVmax) was measured in the breast cancer lesions on 18F-FES PET/CT. |
| Lesions detected by 18F-FES PET/CT | through study completion, an average of 1 year | The number of target lesions was calculated by 18F-FES PET/CT. |
| Compared with 18F-FDG PET/CT | through study completion, an average of 1 year | The number of lesions detected by 18F-FES PET/CT was compared with 18F-FDG PET/CT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 3 years | Evaluate overall survival (OS) in patients receiving regimens containing endocrine therapy |
Countries
China
Contacts
Primary ContactZhixin Hao, M.D.
Backup ContactLi Huo, M.D.
Outcome results
None listed